Precision Medicine in Rare Bleeding Disorders
Akbar Dorgalaleh,Maha Othman
DOI: https://doi.org/10.1055/s-0044-1800833
2024-12-07
Seminars in Thrombosis and Hemostasis
Abstract:Rare bleeding disorders (RBDs) are also referred to by other names, including recessively inherited bleeding disorders, rare coagulation factor deficiencies, and rare congenital bleeding disorders.[1] Traditionally, these disorders include all coagulation factor deficiencies with bleeding tendency, except for hemophilia A and hemophilia B.[1] The estimated incidence of these disorders ranges widely, from 1 per 2 million for factor XIII (FXIII) and prothrombin (FII) deficiency to 1 per 500,000 for FVII deficiency in the general population.[1] [2] Over the last two decades, with rapid progress in laboratory diagnosis, molecular studies, and clinical characterization of bleeding disorders, there have been significant improvements in both case identification and treatment modalities. Additionally, other less common bleeding disorders, characterized by both bleeding tendency and rare incidence, have been included in this category.[1] Today, inherited platelet function disorders, disorders of the fibrinolytic system, and other rare hemorrhagic disorders such as rare forms of von Willebrand disease (VWD) and platelet-type VWD (PT-VWD) can be included in this category. A large number of studies have been conducted on these rare disorders, and a wide range of disease variants have been identified in the underlying genes, illuminating their molecular basis.[3] This progress has advanced significantly from the discovery of the underlying genes for each disorder to the in vitro application of advanced gene editing systems like CRISPR/Cas (clustered regularly interspaced short palindromic repeats/CRISPR-associated).[4] Growth has also occurred in therapeutic options, which have evolved from traditional choices such as whole blood transfusion, platelet concentrate, fresh frozen plasma (FFP), and cryoprecipitate to more advanced options: plasma-derived and recombinant or nanoengineered products that are now available for a considerable number of RBDs.[1] Despite all the advances, the shift in therapeutic intervention from traditional general recommendations to more specific personalized therapeutic recommendations (precision medicine) represents a significant improvement that can enhance the quality of life for these patients, as increasingly observed in hemophilia A and B.[5] The advent of next-generation sequencing (NGS) and genome-wide association studies (GWAS), along with the rapid growth of artificial intelligence (AI), may have a significant impact on this field. The identification of genetic modifiers that can directly affect disease phenotype can further accelerate this progress. Due to the importance of this field and its potential impact, this issue of Seminars in Thrombosis and Hemostasis (STH) aims to cover various aspects of RBDs, including laboratory, clinical, and molecular findings, which can potentially influence personalized patient management. With regard to this, in the first paper of this issue, Cassini et al review the clinical, laboratory, and molecular aspects of congenital fibrinogen disorders (CFDs).[6] The authors report that patients with the same fibrinogen variant may have completely different clinical phenotypes. Additionally, they note some established genotype-phenotype correlations in CFDs, such as thrombotic-related dysfibrinogenemia and fibrinogen storage disease, while suggesting that other potential genetic modifiers may be identified through NGS.[6] Due to the important role of genetics, Franchini and Focosi report that among different types of F5 gene mutations, splice site mutations and those associated with premature codon terminations are associated with severe FV deficiency, while the Met2120Thr polymorphism and the HR2 haplotype are associated with a milder phenotype.[7] There is a poor correlation between FV activity levels and severity of clinical presentations. The optimal treatment of the disorder depends on the clinical severity, with antifibrinolytics for management of mild FV deficiency and replacement therapy with FFP for severe deficiency to increase the FV levels to 20 to 25%.[7] Although concomitant reduction of FV and FVIII would be expected to cause a more severe phenotype than separate single deficiencies of each coagulation factor, this is not the case, as patients with combined FV and FVIII deficiency (CF5F8D) experience a milder phenotype, as pointed out by Yakovleva and Zhang in their review.[8] There is a strong correlation between residual levels of FV and FVIII and the severity of clinical presentations in CF5F8D. However, although patients with MCFD2 mutations have lower plasma FV and FVIII activities, factor activity in CF5F8D cannot be used as a predictor of genotype. The mainstay of treatment in CF5F8D is on-demand therapy, and treatment is based on the severity of clinical pre -Abstract Truncated-
peripheral vascular disease,hematology